Effect of Sodium-Glucose Co-transporter-2 Inhibitors on Ventricular Repolarization Markers in Heart Failure with Reduced Ejection Fraction

Background and Aim Sodium-glucose co-transporter-2 (SGLT2) inhibitors added to optimal medical therapy have been shown to reduce the risk of cardiovascular death and recurrent heart failure (HF) hospitalization in HF patients. We aimed to evaluate the effect of SGLT2 inhibitors on the ventricular re...

Full description

Saved in:
Bibliographic Details
Published in:Cardiovascular drugs and therapy 2024-04, Vol.38 (2), p.327-333
Main Authors: Yılmaz, Emre, Aydın, Ertan, Çamcı, Sencer, Kurt, Devrim, Aydın, Ercan
Format: Article
Language:English
Subjects:
Brain natriuretic peptide
Cardiology
Cardiovascular diseases
Congestive heart failure
Dispersion
Ejection fraction
EKG
Electrocardiography
Glucose
Glucose transporter
Health risks
Health services
Heart failure
Heart Failure - diagnosis
Heart Failure - drug therapy
Humans
Inhibitors
Medical treatment
Medicine
Medicine & Public Health
Orignal Article
Patients
Sodium
Sodium-Glucose Transporter 2 Inhibitors - pharmacology
Stroke Volume
Symporters
Ventricle
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background and Aim Sodium-glucose co-transporter-2 (SGLT2) inhibitors added to optimal medical therapy have been shown to reduce the risk of cardiovascular death and recurrent heart failure (HF) hospitalization in HF patients. We aimed to evaluate the effect of SGLT2 inhibitors on the ventricular repolarization markers (VRM) in patients with HF with reduced ejection fraction (HFrEF). Methods 51 patients with HFrEF who had symptoms New York Heart Association (NYHA) class II–IV despite optimal medical treatment and were added SGLT2 inhibitors to their treatment were included in the study. Electrocardiography (ECG) and laboratory results obtained before the treatment and at the first-month follow-up visit were compared. QT, QTc (corrected by Bazett formula), QT dispersion (QTd), QTc dispersion (QTc-d), Tpeak to Tend (Tp-e) interval, Tp-e/QT, and Tp-e/QTc ratios were measured and defined as VRM. Results A significant decrease was observed in HR, QT, QTc intervals, and QTd compared to pre-treatment. While the mean Tp-e interval was 101.5 ± 11.7 ms before treatment, it decreased to 93.1 ± 12.7 ms after treatment ( p  
ISSN:0920-3206
1573-7241
DOI:10.1007/s10557-022-07396-y